Separately, LADENBURG THALM/SH SH upgraded Ayala Pharmaceuticals from a neutral rating to a buy rating in a research note on Tuesday, May 30th.
Ayala Pharmaceuticals Trading Down 11.2 %
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers.
- Five stocks we like better than Ayala Pharmaceuticals
- How to Analyze Restaurant Stocks
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- How to Invest in Solar Energy
- MarketBeat Week in Review – 9/11 – 9/15
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.